Shares of Editas Medicine Inc. (NASDAQ:EDIT) saw strong trading volume on Thursday . 283,829 shares were traded during mid-day trading, an increase of 31% from the previous session’s volume of 217,243 shares.The stock last traded at $18.00 and had previously closed at $19.06.

Several analysts recently weighed in on the company. Jefferies Group upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Wednesday, August 10th. Zacks Investment Research upgraded Editas Medicine from a “sell” rating to a “hold” rating in a report on Tuesday, July 19th. Cowen and Company restated a “buy” rating on shares of Editas Medicine in a report on Monday, May 16th. Finally, Vetr upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 price objective for the company in a report on Monday, May 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $33.50.

The company’s market cap is $628.78 million. The stock’s 50-day moving average is $24.33 and its 200-day moving average is $29.34.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.54) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.54). Equities research analysts expect that Editas Medicine Inc. will post ($2.59) EPS for the current fiscal year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.